أحدث المنشورات
Tff2 defines transit-amplifying pancreatic acinar progenitors that lack regenerative potential and are protective against Kras-driven carcinogenesis
Cell Stem Cell. 2023 Aug 3;30(8):1091-1109.e7. doi: 10.1016/j.stem.2023.07.002.
Jiang Z, Wu F, Laise P, Takayuki T, Na F, Kim W, Kobayashi H, Chang W, Takahashi R, Valenti G, Sunagawa M, White RA, Macchini M, Renz BW, Middelhoff M, Hayakawa Y, Dubeykovskaya ZA, Tan X, Chu TH, Nagar K, Tailor Y, Belin BR, Anand A, Asfaha S, Finlayson MO, Iuga AC, Califano A, Wang TC.
Exploring the optimal therapeutic management of stage ypIA pancreatic ductal adenocarcinoma patients in the era of primary chemotherapy. Dig Liver Dis
2023 Jul 15:S1590-8658(23)00758-2. doi: 10.1016/j.dld.2023.07.006.
Macchini M, Belfiori G, Crippa S, Orsi G, Gasparini G, Tamburrino D, Partelli S, Schiavo Lena M, Palumbo D, De Cobelli F, Falconi M, Reni M.
Safety and preliminary activity results of the GATTO study, a phase Ib study combining the anti-TA-MUC1 antibody gatipotuzumab with the anti-EGFR tomuzotuximab in patients with refractory solid tumors
ESMO Open. 2022 Apr;7(2):100447. doi: 10.1016/j.esmoop.2022.100447. Epub 2022 Apr 6. Erratum in: ESMO Open. 2022 Aug;7(4):100549.
Ochsenreither S, Fiedler WM, Conte GD, Macchini M, Matos I, Habel B, Ahrens-Fath I, Raspagliesi F, Lorusso D, Keilholz U, Rolling C, Kebenko M, Klinghammer KF, Saavedra O, Baumeister H, Zurlo A, Garralda E.
Treatment opportunities and future perspectives for pancreatic cancer patients with germline BRCA1-2 pathogenic variants
Cancer Treat Rev. 2021 Nov;100:102262. doi: 10.1016/j.ctrv.2021.102262.
Macchini M, Centonze F, Peretti U, Orsi G, Militello AM, Valente MM, Cascinu S, Reni M.
Exploring chemotherapy holiday and drugs re-challenge in advanced pancreatic cancer patients
Cancer Chemother Pharmacol 2021;87:95-101.
Macchini M, Peretti U, Orsi G, Zanon S, Mazza E, Valente MM, Tamburrino D, Belfiori G, Rossi G, Testoni SGG, Passoni P, Doglioni C, Cascinu S, Reni M.
Multidrug regimens for treatment of older patients with metastatic pancreatic cancer
Dig Liver Dis 2020; 20:30269-3.
Macchini M, Chiaravalli M, Pircher C, Zanon S, Peretti U, Mazza E, Valente MM, Fugazza C, Gianni L, Reni M.
Interleukin-1β-induced pancreatitis promotes pancreatic ductal adenocarcinoma via B lymphocyte-mediated immune suppression
Gut. 2020:gutjnl-2019-319912. doi: 10.1136/gutjnl-2019-319912.
Takahashi R*, Macchini M*, Sunagawa M, Jiang Z, Tanaka T, Valenti G, Renz BW, White RA, Hayakawa Y, Westphalen CB, Tailor Y, Iuga AC, Gonda TA, Genkinger J, Olive KP, Wang TC.
Chemotherapy in elderly patients with pancreatic cancer: Efficacy, feasibility and future perspectives
Cancer Treat Rev 2019;72:1-6.
Macchini M, Chiaravalli M, Zanon S, Peretti U, Mazza E, Gianni L, Reni M.
Beta2 adrenergic-neurotrophin feedforwaed loop promotes pancreatic cancer
Cancer Cell 2018;8: 75-90.
Renz BW, Takahashi R, Tanaka T, Macchini M, Hayakawa Y, Dantes Z, Maurer HC, Chen X, Jiang Z, Westphalen CB, Ilmer M, Valenti G, Mohanta SK, Habenicht AJR, Middelhoff M, Chu T, Nagar K, Tailor Y, Casadei R, Di Marco M, Kleespies A, Friedman RA, Remotti H, Reichert M, Worthley DL, Neumann J, Werner J, Iuga AC, Olive KP, Wang TC.
Nab-paclitaxel plus gemcitabine with or without capecitabine and cisplatin in metastatic pancreatic adenocarcinoma (PACT-19): a randomised phase 2 trial
Lancet Gastroenterol Hepatol. 2018;3:691-697
Reni M, Zanon S, Peretti U, Chiaravalli M, Barone D, Pircher C, Balzano G, Macchini M, Romi S, Gritti E, Mazza E, Nicoletti R, Doglioni C, Falconi M, Gianni L
